Angelini Pharma S.p.A.

Plus: Zenas taps Tesaro vet Lakin for CSO job; Lift hires Exley

Plus: Hegde becomes CSO at Congruence, and updates from Medivir and Grunenthal

Plus CEO Sandanayaka shifts to CSO at Nirogy, and updates from Angelini, Apie, 

Angelini Lumira Biosciences Fund will invest in CNS and rare disease therapies

Luciana Borio, the senior fellow for global health at the Council on Foreign Relations, became a member of the scientific advisory board at Coalition for Epidemic Preparedness Innovations (CEPI).

Viral infections company Atea Pharmaceuticals Inc. (NASDAQ:AVIR) hired Claudio Avila as SVP of medical affairs. Avila joins from Gilead Sciences Inc. (NASDAQ:GILD), where he was executive director of

Academia remains the primary source of innovation, but industry spinouts rose in number last year

The European Commission approved Kesimpta ofatumumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat relapsing forms of multiple sclerosis. The subcutaneously administered drug was originally

Kurma Partners, Bpifrance launch French incubator to turn translational projects across Europe into biotech start-ups

Via its $960 million takeout of Swiss CNS play Arvelle, Angelini will gain European rights to a late-stage epilepsy program.  The deal, which includes $610 million in cash up front and up to $350